R

Ultragenyx Pharmaceutical

D
RARE
USD
-0.1
(-0.1979%)
Market Closed
22,780.00
Volume
-6.64
EPS
-
Div Yield
-6.995839
P/E
4,648,812,183.60
Market Cap
Today
-3.3531%
1 Week
-1.059%
1 Month
-3.869%
6 Months
20.267%
12 Months
32.475%
Year To Date
5.512%
All Time
-28.988%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CRIS
0.18
(4.2857%)
USD
F
FATE
-0.24
(-8.6022%)
USD
S
SRPT
-7.62
(-5.9531%)
USD
B
BLUE
-0.0729
(-16.2614%)
USD
V
VCYT
0.78
(2.1317%)
USD
C
CLRB
0.045
(2.1739%)
USD
M
MGTX
0.33
(5.1482%)
USD
V
VCEL
1.985
(4.1311%)
USD
K
KRYS
2.78
(1.5199%)
USD

Title:
Ultragenyx Pharmaceutical

Sector:
Healthcare
Industry:
Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Do you need help or have a question?
Contact Us